CSL Limited
https://www.csl.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CSL Limited
ARS Gets Early FDA Approval For Needle-Free Epinephrine
ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.
Gene Therapy Patient Pipeline Builds, But Slowly, In Q2
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
ARS Gets Early FDA Approval For Needle-Free Epinephrine
ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.
UniQure Keeps Cutting Costs With 300 More Jobs To Go
The company will cut 65% of its workforce to extend its cash runway and focus its resources on AMT-130 for Huntington's disease and three earlier-stage programs moving into Phase I/II studies.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
-
- bioCSL
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Seqirus
- Wuhan Zhong Yuan Rui De Biological Products
- Ruide
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice